• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 6747 Citations
  • 40 h-Index
20012019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 8 Similar Profiles
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
Survival Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Juric, D., Janku, F., Rodon Ahnert, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., Bootle, D., Demanse, D., Blumenstein, L., Schumacher, K., Huang, A., Quadt, C. & Rugo, H. S., Feb 1 2019, In : JAMA Oncology. 5, 2

Research output: Contribution to journalArticle

Estrogen Receptors
Clinical Trials
Breast Neoplasms
Maximum Tolerated Dose
Phosphatidylinositol 3-Kinase

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

Liang, W. S., Vergilio, J. A., Salhia, B., Huang, H. J., Oki, Y., Garrido-Laguna, I., Park, H., Westin, J. R., Meric-Bernstam, F., Fabrizio, D., Miller, V. A., Stephens, P. J., Fanale, M. A., Ross, J. S. & Janku, F., Feb 1 2019, In : Oncologist. 24, 2, p. 219-228 10 p.

Research output: Contribution to journalArticle

Hodgkin Disease
Mutation
Genes
Plasma Cells
Gene Frequency

Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)

Berry, S., Giraldo, N., Nguyen, P., Green, B., Xu, H., Ogurtsova, A., Soni, A., Succaria, F., Wang, D., Roberts, C., Stein, J., Engle, E., Pardoll, D., Anders, R., Cottrell, T., Taube, J. M., Tran, B., Voskoboynik, M., Kuo, J., Bang, Y. L. & 72 othersChung, H. C., Ahn, M. J., Kim, S. W., Perera, A., Freeman, D., Achour, I., Faggioni, R., Xiao, F., Ferte, C., Lemech, C., Meric-Bernstam, F., Werner, T., Hodi, S., Messersmith, W., Lewis, N., Talluto, C., Dostalek, M., Tao, A., McWhirter, S., Trujillo, D., Luke, J., Xu, C., Bomarelli, B., Qi, J., Qin, G., Yu, H., Jenkins, M., Lo, K. M., Halle, J. P., Lan, Y., Taylor, M., Vogelzang, N., Cohn, A., Stepan, D., Shumaker, R., Dutcus, C., Guo, M., Schmidt, E., Rasco, D., Brose, M., Di Simone, C., Jain, S., Richards, D., Encarnacion, C., Vogelzeng, N., Mier, J., An, J., Yang, Y. Y., Lee, W. H., Yang, J., Kim, J. K., Kim, H. G., Paek, S. H., Lee, J. W., Woo, J., Kim, J. B., Kwon, H., Lim, W., Paik, N. S., Kim, Y. K., Moon, B. I., Janku, F., Tan, D., Martin-Liberal, J., Takahashi, S., Geva, R., Gucalp, A., Chen, X., Subramanian, K., Mataraza, J., Wheler, J. & Bedard, P., Feb 13 2019, In : Journal for immunotherapy of cancer. 7, 1, 46.

Research output: Contribution to journalArticle

Open Access
Immunotherapy
Publications
Neoplasms

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies

Bhatty, M., Kato, S., Piha-Paul, S. A., Naing, A., Subbiah, V., Huang, H. J., Karp, D. D., Tsimberidou, A. M., Zinner, R. G., Hwu, W-J., Javle, M., Patel, S. P., Hu, M. I-N., Varadhachary, G. R., Conley, A. P., Ramzanali, N. M., Holley, V. R., Kurzrock, R., Meric-Bernstam, F., Kwang Chae, Y. & 3 othersKim, K. B., Falchook, G. S. & Janku, F., Feb 1 2019, In : Cancer. 125, 3, p. 463-472 10 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Melanoma
Mitogen-Activated Protein Kinase Kinases
Neoplasms

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

Hong, D. S., LoRusso, P., Hamid, O., Janku, F., Kittaneh, M., Catenacci, D. V. T., Chan, E., Bekaii-Saab, T., Gadgeel, S. M., Loberg, R. D., Amore, B. M., Hwang, Y. C., Tang, R., Ngarmchamnanrith, G. & Kwak, E. L., Apr 15 2019, In : Clinical Cancer Research. 25, 8, p. 2403-2413 11 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Neoplasms
Headache
AMG-337
Nausea